The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Bladder Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines
Abstract
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non–muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.010 · Cited by 2,514
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Self-citationEnfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Powles, T., Valderrama, B. P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., Park, S. H., Shin, S. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312117 · Cited by 1,103
Self-citationMoch, H., Amin, M. B., Berney, D. M., Compérat, E. M., Gill, A. J., Hartmann, A., Menon, S., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.06.016 · Cited by 846
BÖHLE, A., JOCHAM, D., & BOCK, P. R. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)64043-8 · Cited by 616
Balar, A. V., Kamat, A. M., Kulkarni, G. S., Uchio, E. M., Boormans, J. L., Roumiguié, M., Krieger, L. E. M., Singer, E. A., Bajorin, D. F., Grivas, P., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00147-9 · Cited by 565
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., Beuzeboc, P., Bedke, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309863 · Cited by 511
Boorjian, S. A., Alemozaffar, M., Konety, B. R., Shore, N. D., Gomella, L. G., Kamat, A. M., Bivalacqua, T. J., Montgomery, J. S., Lerner, S. P., Busby, J. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30540-4 · Cited by 480
Self-citationShelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004) · BJU International · doi:10.1111/j.1464-410x.2003.04655.x · Cited by 342
Han, R. F., & Pan, J. G. (2006) · Urology · doi:10.1016/j.urology.2005.12.014 · Cited by 340
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Houede, N., Banek, S., Guadalupi, V., Ku, J. H., Valderrama, B. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308849 · Cited by 340
Self-citationNetto, G. J., Amin, M. B., Berney, D. M., Compérat, E. M., Gill, A. J., Hartmann, A., Menon, S., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.002 · Cited by 316
Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., & Mason, M. D. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02306.x · Cited by 313
van der Meijden, A. P. M., Sylvester, R. J., Oosterlinck, W., Hoeltl, W., & Bono, A. V. (2003) · European Urology · doi:10.1016/s0302-2838(03)00357-9 · Cited by 305
Packiam, V. T., Lamm, D. L., Barocas, D. A., Trainer, A., Fand, B., Davis, R. L., Clark, W., Kroeger, M., Dumbadze, I., Chamie, K., et al. (2018) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.07.005 · Cited by 249
Pasin, E., Josephson, D. Y., Mitra, A. P., Côté, R. J., & Stein, J. P. (2008) · Europe PMC (PubMed Central) · Cited by 204
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
Chamie, K., Chang, S. S., Kramolowsky, E., Gonzalgo, M. L., Agarwal, P. K., Bassett, J. C., Bjurlin, M., Cher, M. L., Clark, W., Cowan, B. E., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200167 · Cited by 177
Self-citationSiefker-Radtke, A. O., Necchi, A., Park, S. H., García-Donas, J., Huddart, R. A., Burgess, E. F., Fleming, M. T., Rezazadeh Kalebasty, A., Mellado, B., Varlamov, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00660-4 · Cited by 171
Self-citationCancer Susceptibility Mutations in Patients With Urothelial Malignancies
Carlo, M. I., Ravichandran, V., Srinavasan, P., Bandlamudi, C., Kemel, Y. M., Ceyhan‐Birsoy, O., Mukherjee, S., Mandelker, D. L., Chaim, J. L., Knežević, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01395 · Cited by 149
Veskimäe, E., Linares, E., Bruins, H. M., Yuan, Y., Sylvester, R. J., Kamat, A. M., Shariat, S. F., Witjes, J. A., & Compérat, É. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.09.003 · Cited by 139
Bladder cancer risk from occupational and environmental exposures
Kiriluk, K. J., Prasad, S. M., Patel, A. R., Steinberg, G. D., & Smith, N. D. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.10.010 · Cited by 115
Siefker-Radtke, A. O., Matsubara, N., Park, S. H., Huddart, R. A., Burgess, E. F., Özgüroğlu, M., Valderrama, B. P., Laguerre, B., Basso, U., Triantos, S., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.003 · Cited by 102
Self-citationIntravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer
Schmidt, S., Kunath, F., Coles, B., Draeger, D. L., Krabbe, L., Dersch, R. S., Kilian, S., Jensen, K., Dahm, P., & Meerpohl, J. J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011935.pub2 · Cited by 60
Parizi, M. K., Margulis, V., Compérat, É., & Shariat, S. F. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.08.023 · Cited by 16
Metadata
- Authors
- Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Buyyounouski, M. K., Chan, K., Chang, S. S., Chang, P., Friedlander, T., Greenberg, R. E., Guru, K. A., Herr, H. W., Hoffman-Censits, J., Kaimakliotis, H., Kishan, A. U., Kundu, S., Lele, S. M., Mamtani, R., Mian, O. Y., Michalski, J., Montgomery, J. S., Parikh, M., Patterson, A., Peyton, C., Plimack, E. R., Preston, M. A., Richards, K., Sexton, W. J., Siefker-Radtke, A. O., Stewart, T., Sundi, D., Tollefson, M., Tward, J., Wright, J. L., Cassara, C. J., & Gurski, L. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2024-05
- Volume
- 22
- Issue
- 4
- Pages
- 216-225
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4396955712
- Cited by
- 273
- References
- 25
- FWCI
- 97.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.